Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapy for treatment of cancer

A technology of cancer, therapeutic agent, applied in the field of combination therapy for the treatment of cancer, capable of solving problems such as undifferentiated, uncontrolled proliferation

Inactive Publication Date: 2017-05-24
ONCOMED PHARMA INC
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Activation of the Wnt pathway may maintain tumor cells in an undifferentiated state and / or lead to uncontrolled proliferation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy for treatment of cancer
  • Combination therapy for treatment of cancer
  • Combination therapy for treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0298] Activity of FZD8-Fc Soluble Receptor OMP-54F28 in Combination with Chemotherapeutic Agents in Vivo

[0299] The OncoMed xenograft models described herein were established at OncoMed Pharmaceuticals from minimally passaged patient-derived tumor specimens. Tumor samples are examined by a pathologist and classified into specific tumor types. OncoMed relies on these classifications unless further analysis is performed on any particular tumor and reclassification is deemed warranted.

[0300] Xenograft OMP-OV19 ovarian tumor cells (1×10 5 cells) were injected subcutaneously into 6-8 week-old NOD / SCID mice. Tumors were grown for 28 days until they reached 120mm 3 average volume. Mice were randomly divided into groups (n=9 per group) and treated with paclitaxel, nab-paclitaxel, carboplatin, combination of carboplatin and paclitaxel, combination of OMP-54F28 and paclitaxel, combination of OMP-54F28 and nab-paclitaxel Mice were treated with the combination, the combination ...

Embodiment 2

[0305] Effect of Staggered Dosing Regimen on the Activity of Anti-FZD Antibody OMP-18R5 in Combination with Paclitaxel

[0306] Single cell suspensions of xenografted UM-PE13 mammary tumor cells (20,000 cells) were injected subcutaneously into 6-8 week old NOD / SCID mice. UM-PE13 is a type of triple negative breast cancer. Tumors were allowed to grow for 34 days until they reached an average of 80mm 3 volume of. Mice were randomly divided into groups (n=8 per group) and treated with paclitaxel, a combination of OMP-18R5 and paclitaxel administered on the same day, a combination of OMP-18R5 and paclitaxel (where paclitaxel was administered 3 days before the administration of OMP-18R5), A combination of OMP-18R5 and paclitaxel (wherein OMP-18R5 was administered 3 days prior to paclitaxel administration), or a control antibody treated mice. Mice were treated every three weeks with OMP-18R5 at a dose of 25 mg / kg and paclitaxel at a dose of 20 mg / kg. OMP-18R5 and paclitaxel were...

Embodiment 3

[0310] Effect of Staggered Dosing Regimen on the Activity of FZD8-Fc Soluble Receptor OMP-54F28 in Combination with Paclitaxel

[0311] Xenograft OMP-OV38 ovarian tumor cells (1×10 5 cells) were injected subcutaneously into 6-8 week-old NOD / SCID mice. Tumors were grown for 38 days until they reached 140mm 3 average volume. Mice were randomly divided into groups (n=9 per group) and treated with paclitaxel, a combination of OMP-54F28 and paclitaxel administered on the same day, a combination of OMP-54F28 and paclitaxel (where paclitaxel was administered 2 days before the administration of OMP-54F28), OMP Mice were treated with a combination of 54F28 and paclitaxel (where OMP-54F28 was administered 2 days prior to paclitaxel administration) or a control antibody. Mice were treated biweekly with OMP-54F28 at a dose of 25 mg / kg and paclitaxel at a dose of 20 mg / kg. OMP-54F28 and paclitaxel were administered intraperitoneally. Tumor growth was monitored and tumor volume was mea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods comprising combination therapy for treating cancer. Wnt pathway inhibitors in combination with mitotic inhibitors administered in a staggered or sequential dosing manner for the treatment of cancer and other diseases.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Application No. 62 / 042,710, filed August 27, 2014, U.S. Provisional Application No. 62 / 086,376, filed December 2, 2014, and U.S. Provisional Application No. 62 / 086,376, filed December 2, 2015. Priority of .62 / 134,661, each of which is incorporated by reference in its entirety. technical field [0003] The present invention provides methods for treating cancer comprising combination therapy. In particular, the invention provides methods comprising a Wnt pathway inhibitor in combination with an inhibitor of mitosis for the treatment of cancer and other diseases. Background technique [0004] Cancer is one of the leading causes of death in developed countries, with approximately 1.6 million people diagnosed with cancer and over 500,000 deaths each year in the United States alone. Overall, more than 1 in 3 people are expected to develop some form of cancer during their lifetime. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K39/395A61K31/337A61P35/00
CPCA61K39/395A61K31/337C07K16/2863A61K2039/505A61K2039/545C07K2317/56C07K2317/565A61K38/177A61K31/475A61P35/00A61K2300/00C07K16/30C07K2317/73
Inventor 奥斯丁·格尼颜婉清
Owner ONCOMED PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com